City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting City of Hope’s groundbreaking Phase 1 clinical trial has demonstrated promising results for patients suffering from colorectal and appendiceal cancer that has metastasized to the peritoneum. As one of…
LGM Pharma Invests $6 Million to Expand U.S. Drug Manufacturing Capabilities LGM Pharma, a leading provider of tailored active pharmaceutical ingredient (API) and contract development and manufacturing organization (CDMO) services, has announced a significant investment of over $6 million to…
Tenpoint Therapeutics Names Carol Kearney as Chief Commercial Officer Tenpoint Therapeutics Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company dedicated to pioneering treatments that rejuvenate vision in the aging eye, has announced the appointment of Carol Kearney as Chief Commercial Officer…
Noramco Group Invests $25M in Halo Pharma for Sterile Injectables The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Establish Sterile Injectable Manufacturing The Noramco Group, a fully integrated North American-based supplier of active pharmaceutical ingredients (APIs)…
ZYUS Life Sciences Closes Unsecured Loan and Amends Previous Loans ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the research, development, and commercialization of innovative cannabinoid-based pharmaceutical drug candidates for pain…
Frazier Life Sciences Names Gerald Nepom as Senior Advisor Frazier Life Sciences (FLS), a premier investment firm dedicated to advancing groundbreaking therapeutics, has appointed Gerald (Jerry) Nepom, M.D., Ph.D., as Senior Advisor. This strategic addition brings an esteemed expert in…
Xeris Biopharma Reports Record Q4 and Full-Year 2024 Results, Sets 2025 Guidance Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly growing biopharmaceutical company dedicated to improving patient lives by developing and commercializing innovative therapies, has announced record-breaking financial results for…
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy Italfarmaco S.p.A., a global pharmaceutical company dedicated to developing innovative treatments for rare diseases, has provided a comprehensive update on the regulatory and clinical advancements of givinostat, its investigational therapy for Duchenne…
Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the pioneering leader in RNA interference (RNAi) therapeutics, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company’s Board…
Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair Orbis Medicines, a pioneering leader in oral macrocycle drug discovery, has announced the appointment of Mikael Dolsten, M.D., Ph.D., as Chairperson of the Board of Directors. Dr. Dolsten, the former…
Bionova Launches New Process Development and Pilot Plant in Fremont Bionova Scientific, an Asahi Kasei company and boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has officially announced the opening of a new state-of-the-art facility in Fremont, California. Spanning…
Cadrenal Therapeutics Partners with Abbott for Pivotal Tecarfarin Study in HeartMate 3™ LVAD Patients Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company specializing in the development of cardiovascular therapeutics, has announced a collaboration agreement with Abbott (NYSE: ABT) to…